子宫颈癌患者新辅助化疗前后癌组织中mdr1、肺耐药蛋白mRNA及其蛋白的表达变化和意义

目的寻找预测子宫颈癌新辅助化疗效果的分子生物学指标。方法采用real time RT—PCR和免疫组织化学法检测40例子宫颈癌患者新辅助化疗前后癌组织中mdr1、肺耐药蛋白（LRP）mRNA及其编码蛋白P-gP、LRP表达水平。结果新辅助化疗前后子宫颈癌组织中mdr1的表达量分别为（45．800±0．636、62．381±0．743，t=-66．582，P〈0．01）；新辅助化疗前后子宫颈癌组织中LRP mRNA的表达量分别为（50．048±0．770、66．912±0．752，t=-78．604，P〈0．01）；新辅助化疗前后子宫颈癌组织中P-gP的阳性表达分别为40．0％（16／40）、70．0％（28／40），x^2=7．273，P=0．007；新辅助化疗前后子宫颈癌组织中LRP的阳性表达分别为62．5％（25／40）、92．5％（37／40），x^2=10．323，P=0．001，新辅助化疗后mdr1、LRPmRNA及其编码蛋白P-gP、LRP表达水平较化疗前明显升高，2组比较差异有统计学意义（P〈0．01）。P-gP、LRP表达与患者年龄、肿瘤大小、临床分期、病理分级无关（P〉0．05）；P-gP蛋白的阳性与阴性患者其化疗有效率分别为6（37．5％）、17（70．8％），2组比较差异有统计学意义（x^2=4．365，P〈0．05）。LRP蛋白的阳性与阴性患者其化疗有效率分别为12（48．0％）、13（86．7％），2组比较差异有统计学意义（x^2=5．980，P〈0．05）；P-gP与LRP成正相关（x^2=4．177，r=0．323，P〈0．05）。结论P-gP、LRP表达状态有可能作为预测化疗效果的参考指标。

Expression and significance of mdrl and lung resistance protein mRNA in cervical carcinoma before and after neoadjuvant chemotherapy.

Objective To explore the biological parameter predicting the effect of neoadjuvant chemotherapy in cervieal carcinoma. Methods The expressions of the P-glueoprotein （P-gp） and lung resistance protein （LRP） as well mdrl and LRP mRNA were examined by real time RT-PCR and immunohistochemical assay in 40 specimens of cervical carcinoma before and after neoadjuvant ehemotherapy. Results The expression level of mdrl was [ （45. 800 ± 0.636 ） vs （62.381 ± 0.743 ）, t = - 66. 582, P 〈 0.01 ], the expression level of LRP mRNA was [ 50.048 ± 0.770,66. 912 ± 0.752, t = - 78. 604, P 〈 0.01 ] before and after neoadjuvant chemotherapy The positive expression of P-gp was[ 40.0% （16 /40）,70.0% （28/40）, x^2 = 7. 273, P = 0. 007 ] and that of LRP was [62.5% （25/40） ,92.5% （37/40） ,x^2 = 10.323 ,P =0.001 ] ,which were significantly higher than that before neoadjuvant chemotherapy （ P 〈 0.01 ） ; the expressions of P-gp and LRP were irrelated to age, tumor size, TNM stage and pathology grade（P 〉 0.05 ） ; the effeetive rate of chemotherapy was 6 （ 37.5% ） in P-gp positive patients and 17 （70.8%）in P-gp negative patients （ x^2 = 4. 365, P 〈 0.05 ）, while the effective rate of chemotherapy was 12 （48.0%） in LRP positive patients and 13 （ 86.7 % ） in LRP negative patients （ x^2 = 5. 980, P 〈 0.05 ）. The expression of P-gp was positively correlated with the expressions of LRP （ x^2 = 4. 177, r = 0.323,P 〈 0.05 ）. Conclusion The P-gp and LRP expression status can be used as a biological parameter to predict the effect of neoadjuvant chemotherapy.